Trisomy 13, trisomy 13 test, trisomy 13 screening

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Trisomy 13

Non-Invasive Trisomy 13 Screening For Early Pregnancy Risk Assessment

One crucial aspect of mitigating the risks associated with pregnancy is ensuring that you screen for potential complications including Fetal Patau Sydrome (Trisomy 13). As an alternative to invasive methods such as amniocentesis procedures, Eurofins Biomnis offers Patau Syndrome prenatal diagnosis tests that deliver fast and accurate results. This NIPT (non-invasive prenatal testing) procedure draws analysis from a maternal blood sample, and can be undertaken starting at only 10 weeks ofpregnancy. By choosing our non-invasive Trisomy 13 screening test, it can be easily and safely determined whether the risk of fetal defects from Patau Syndrome is high or low, reducing the need for invasive procedures by up to 95%.

Although Down Syndrome gets more attention in the media as a relatively common fetal disorder, it is equally important for pregnant women to schedule a Trisomy 13 test, in order to rule out risks for the condition more commonly known as Patau Syndrome. While many expectant parents are concerned about the potential risks associated with amniocentesis tests for trisomy, effective non-invasive counterparts are now readily available. Safe, reliable, and rapid, the Eurofins Biomnis NIPT trisomy 13 test can be obtained starting in only the tenth week of pregnancy. They simultaneously detect risks for trisomies 13, 18 and 21, while limiting or altogether eliminating the need for invasive prenatal screenings.

To rule out common pregnancy risks including Fetal Patau syndrome, scheduling a non-invasive Trisomy 13 screening with a primary care physician or other healthcare provider offers patients a safe alternative to procedures such as amniocentesis, which carry some risk of losing the foetus. In addition to Trisomy 13 screening, Biomnis also offers Down Syndrome tests that can be ordered to your physician's practice and carried out there, or at a Biomnis partner laboratory. During your consultation, your healthcare provider will prescribe an NIPT and ask you to sign an informed consent form, which is mandatory for all genetic tests. The procedure is quick, painless, and offers considerable peace of mind.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%